William Blair upgraded Zealand Pharma (ZLDPF) to Outperform from Market Perform without a price target The firm sees the recent share pullback as creating a more favorable risk/reward profile given its “bull stance” on Amylin.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma upgraded to Outperform from Market Perform at William Blair
- Zealand Pharma removed from European Conviction List at Goldman Sachs
- Zealand Pharma initiated with a Market Perform at William Blair
- Zealand Pharma price target lowered to DKK 1,050 from DKK 1,080 at Berenberg
- Zealand Pharma’s Earnings Call: Clinical Gains and Challenges